

Kite Pharmaceuticals, Inc. Investor Relations Department 2225 Colorado Ave Santa Monica, CA 90404 United States

Visit IR website ☐ Sign-up for Email alerts ☐

98.05
4:00 PM ET Jun 27, 2017
-2.38 🖶 (-2.370%)
97.70 - 103.65
39.82 - 101.63
1,791,283

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Stock Performance



Press Releases [View all]

Jun 27, 2017

<u>Kite Named to the MIT Technology Review's Annual 50</u> <u>Smartest Companies List in Recognition for its Leadership in Establishing CAR-T Therapy</u>

Jun 6, 2017

Kite to Present at June 2017 Investor Conferences

Jun 5, 2017

Kite Reports 73 Percent of Patients Achieved MRD

Negative Complete Remission in Updated Analysis From

Phase 1 ZUMA-3 CAR-T Trial of KTE-C19 in Adult Patients

With High Burden Relapsed/Refractory Acute

Lymphoblastic Leukemia

May 26, 2017

<u>Kite Receives U.S. Food and Drug Administration Priority</u> <u>Review for Axicabtagene Ciloleucel</u>

May 17, 2017

<u>Kite Announces Presentations on Its Lead CAR-T Therapy</u>

<u>Development Program at the 2017 American Society of Clinical Oncology Annual Meeting</u>

Financials [View all]

First Quarter Financial Results

Feb 28, 2017

Annual Report (10-K)

Apr 28, 2017

Proxy Statement (DEF 14A)

May 8, 2017

Quarterly Report (10-Q)

Nov 9, 2016

Quarterly Report (10-Q)

Aug 8, 2016

Quarterly Report (10-Q)